High Price of Popular Diabetes Drugs Deprives Low-Income People of Effective Treatment By Renuka Rayasam MAY 21, 2024

https://kffhealthnews.org/news/article/high-prices-ozempic-mounjaro-wegovy-glp1s/?utm_campaign=KHN%20-%20Weekly%20Edition&utm_medium=email&_hsenc=p2ANqtz-94NYqS72mTB5EHWN1BgNJp677vJpUe42tXwafYTU9sMy5Ba7VUvdGx_pwJbRf2Aqt89wRVJ5HR5KNe0_3uua4xf25Tdw&_hsmi=308623498&utm_content=308623498&utm_source=hs_email By Renuka Rayasam The makers of Ozempic and Mounjaro charge list prices of around $1,000 a month for the diabetes and obesity drugs, and insurers are reluctant to pick up the tab. Often, low-income patients have to resort to less effective treatments.